Immunome financials
$21.89+0.97%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 |
|---|---|---|---|---|---|---|
| Revenue | $6.9M | $9.0M | $14.0M | $0.00 | — | — |
| Gross profit | $6.9M | $9.0M | -$66.8M | $0.00 | — | — |
| Gross margin | 100.0% | 100.0% | −476.4% | — | — | — |
| Operating income | -$224.1M | -$305.8M | -$109.5M | -$36.9M | -$25.2M | -$12.3M |
| Net income | -$212.4M | -$293.0M | -$106.8M | -$37.5M | -$24.7M | -$17.8M |
| Net margin | −3060.0% | −3240.4% | −761.9% | — | — | — |
| Diluted EPS | $-2.43 | $-5.00 | $-5.38 | $-3.09 | $-2.14 | $-5.26 |
| EBITDA | -$221.6M | -$304.2M | -$109.1M | -$36.9M | -$24.4M | -$11.5M |
| Operating cash flow | -$190.9M | -$110.8M | -$7.6M | -$28.7M | -$18.2M | -$12.1M |
| Free cash flow | -$200.6M | -$118.0M | -$8.4M | -$28.9M | -$18.3M | -$12.7M |
| Diluted shares | 87.4M | 58.6M | 19.8M | 12.1M | 11.5M | 3.4M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $653.5M | $143.4M | $98.7M | $20.3M | $49.2M | $39.8M |
| Short-term investments | $0.00 | $74.0M | $39.5M | $0.00 | — | — |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $613.0K |
| Total assets | $683.2M | $240.2M | $148.5M | $24.0M | $57.9M | $44.5M |
| Total liabilities | $48.8M | $59.1M | $28.7M | $7.4M | $9.7M | $3.2M |
| Shareholders' equity | $634.3M | $181.2M | $119.9M | $16.7M | $48.2M | $41.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology